Advertisement

Indian Journal of Gastroenterology

, Volume 37, Issue 3, pp 215–225 | Cite as

Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis

  • Cyriac Abby Philips
  • Nikhil Phadke
  • Karthik Ganesan
  • Shatakshi Ranade
  • Philip Augustine
Original Article

Abstract

Introduction

Alcohol-induced intestinal dysbiosis is central to the development of the severe alcoholic liver disease. We present the first study to compare outcomes in patients of severe alcoholic hepatitis (SAH) on nutritional therapy, corticosteroids, pentoxifylline, and healthy donor fecal transplantation (FMT) and discuss distinct microbial community and microbiome metabolic functional changes after FMT.

Methods

Out of 1271 liver disease patients, 809 (63.7%) were diagnosed to have the alcoholic liver disease, of which 51 patients (8 treated with corticosteroids, 17 with nutritional support only, 10 with pentoxifylline, 16 receiving FMT) were included. Clinical, biochemical parameters, liver disease, and alcoholic hepatitis severity scores at baseline and mortality at the end of 1 and 3 months were analyzed between groups. Stool microbiota (SM) analysis was performed for healthy controls (HC) and respective recipients after FMT.

Results

All the patients were male. The proportions of patients surviving at the end of 1 and 3 months in the steroids, nutrition, pentoxifylline, and FMT group were 63%, 47%, 40% and 75% [p = 0.179] and 38%, 29%, 30%, and 75% [p = 0.036], respectively. When compared with FMT, relative risk and hazard ratios for death were higher in all the other groups. Following FMT, distinct and beneficial modulation of SM and pathways of dysregulated metabolism, infections, inflammation, and oxidative stress in SAH patients were noted in tandem with improved clinical outcomes.

Conclusions

Healthy donor FMT for SAH improves survival beyond what is offered by current therapies and can function as a cost-effective bridge to liver transplant (LT) or for improving transplant-free survival. Larger studies and randomized trials are unmet needs.

Keywords

Alcoholic hepatitis Corticosteroids Dysbiosis Gut microbiome Intestinal microbiota Liver transplant Metagenomics Sequencing Stool transplant 

Notes

Compliance with ethical standards

Conflict of interest

CAP, NP, KG, SR, and PA declare that they have no conflict of interest.

Ethics statement

All procedures performed in studies involving human participants were by the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

12664_2018_859_MOESM1_ESM.docx (20 kb)
ESM 1 (DOCX 20 kb)
12664_2018_859_MOESM2_ESM.docx (17 kb)
ESM 2 (DOCX 16 kb)
12664_2018_859_MOESM3_ESM.docx (15 kb)
ESM 3 (DOCX 14 kb)
12664_2018_859_MOESM4_ESM.docx (15 kb)
ESM 4 (DOCX 15 kb)
12664_2018_859_MOESM5_ESM.docx (16 kb)
ESM 5 (DOCX 15 kb)
12664_2018_859_Fig6_ESM.png (1 mb)
ESM 6

(PNG 1042 kb)

12664_2018_859_MOESM6_ESM.tif (2.7 mb)
High resolution image (TIF 2772 kb)

References

  1. 1.
    Crabb DW, Bataller R, Chalasani NP, et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology. 2016;150:785–90.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75:193–9.PubMedGoogle Scholar
  3. 3.
    Mathurin P, O’Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011;60:255–60.CrossRefPubMedGoogle Scholar
  4. 4.
    Vergis N, Knapp S, Maurice J, et al. In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA. Gastroenterology. 2017;152:1068–77.CrossRefPubMedGoogle Scholar
  5. 5.
    Addolorato G, Bataller R, Burra P, et al. Liver transplantation for alcoholic liver disease. Transplantation. 2016;100:981–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Hartl J, Scherer MN, Loss M, et al. Strong predictors for alcohol recidivism after liver transplantation: non-acceptance of the alcohol problem and abstinence of <3 months. Scand J Gastroenterol. 2011;46:1257–66.CrossRefPubMedGoogle Scholar
  7. 7.
    Sidhu SS, Goyal O, Kishore H, Sidhu S. New paradigms in management of alcoholic hepatitis: a review. Hepatol Int. 2017;11:255–67.CrossRefPubMedGoogle Scholar
  8. 8.
    Ferrere G, Wrzosek L, Cailleux F, et al. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice. J Hepatol. 2017;66:806–15.CrossRefPubMedGoogle Scholar
  9. 9.
    Philips CA, Pande A, Shasthry SM, et al. Healthy donor fecal microbiota transplantation in steroid ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol. 2017;15:600–2.CrossRefPubMedGoogle Scholar
  10. 10.
    Llopis M, Cassard AM, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut. 2016;65:830–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Moreno C, Deltenre P, Senterre C, et al. Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids. Gastroenterology. 2016;150:903–10.e8.CrossRefPubMedGoogle Scholar
  12. 12.
    Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372:1619–28.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Nakahara T, Hyogo H, Ono A, et al. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease. J Gastroenterol. 2018;53:269–80.CrossRefPubMedGoogle Scholar
  15. 15.
    Chen Y, Ji F, Guo J, Shi D, Fang D, Lib L. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci Rep. 2016;6:34055.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology. 2016;64:1265–72.CrossRefPubMedGoogle Scholar
  17. 17.
    Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54:562–72.CrossRefPubMedGoogle Scholar
  18. 18.
    Bajaj JS, Ridlon JM, Hylemon PB, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2012;302:G168–75.CrossRefPubMedGoogle Scholar
  19. 19.
    Bajaj JS, Hylemon PB, Heuman DM, et al. The cirrhosis dysbiosis ratio defines changes in the gut microbiome associated with cirrhosis and its complications. Hepatology. 2014;60:940–7.CrossRefGoogle Scholar
  20. 20.
    Li SS, Zhu A, Benes V, et al. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science. 2016;29:586–9.CrossRefGoogle Scholar
  21. 21.
    Oikawa T. Alanine, aspartate, and asparagine metabolism in microorganisms. In: Wendisch VF. eds. Amino acid biosynthesis—pathways, regulation and metabolic engineering. Microbiology Monographs. Vol 5. 2006. Springer, Berlin, Heidelberg.Google Scholar
  22. 22.
    Calder PC. Branched-chain amino acids and immunity. J Nutr. 2006;136 1 Suppl:288S–93S.Google Scholar
  23. 23.
    Tajiri K, Shimizu Y. Branched-chain amino acids in liver diseases. World J Gastroenterol. 2013;19:7620–9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Neuman MG, Maor Y, Nanau RM, et al. Alcoholic liver disease: role of cytokines. Biomolecules. 2015; 5: 2023–34.Google Scholar
  25. 25.
    Odena G, Chen J, Lozano JJ, et al. LPS-TLR4 pathway mediates ductular cell expansion in alcoholic hepatitis. Sci Rep. 2016;6:35610.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2018

Authors and Affiliations

  • Cyriac Abby Philips
    • 1
  • Nikhil Phadke
    • 2
  • Karthik Ganesan
    • 3
  • Shatakshi Ranade
    • 2
  • Philip Augustine
    • 4
  1. 1.The Liver Unit, Cochin Gastroenterology GroupErnakulam Medical CentreKochiIndia
  2. 2.Molecular, Cellular and Developmental BiologyGenepath-DxPuneIndia
  3. 3.Helical BíoAnn ArborUnited States of America
  4. 4.Gastroenterology, Cochin Gastroenterology GroupErnakulam Medical CentreKochiIndia

Personalised recommendations